Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RAND Report Recommends Case-Control Ephedra Study Look At AE Risk

This article was originally published in The Tan Sheet

Executive Summary

A case-control study examining the risk of serious adverse events related to the use of ephedra and ephedrine alkaloid-containing dietary supplements would fill a vital gap in the current body of research on the supplement ingredient, the RAND report states

You may also be interested in...



NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says

NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act

NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says

NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act

NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says

NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS095223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel